The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
It's really baffling......... floating on NASDAQ cost 40m or something effectively and we're up ****s creek without a paddle over a 10/12m debt/mortgage with strict terms.
The Times reckon Interpath will hunt for a buyer.
It is indeed absolutely baffling how a chat on the 23rd can end up in Oxford forcing administration on the 24th. It can only be a tiny part of the story.
I'm down a nice few quid but I'm agreed that the main concern is for folk who were looking to this as a potential life extender ........... Keytruda is that and any combination drugs etc are afaik to make it more efficacious to more folk
I'd imagine shorters will be in deep **** after 10am
the absence of a significant seller alone should allow drift back to £1 over the coming weeks without news IMO. With good news you'd imagine we'll take off ... I'd not be able to guess at quantifying what take off is TBH but it's North of £1
Merck aren't investors in this as a punt IMO
"If I thought this was only going to 5x I wouldn't still be here" .......... indeed, like the rest of us though when we were at £1.40 not too long ago you hardly thought we'd be at 40p now.
Unfortunately the market is highly irrational. The current loony low SP will facilitate rises no doubt but we do need to multibag from here to get back to previous "highs"... and those previous highs I thought were loony low also.
Really well needs to be a 5 bagger from here though for most PIs I imagine.
Welcome along...."waiting for a good buy in price which was finally today!".... Surely Tuesday at 10% lower appealed if you were waiting a while?
At these levels I can't see you making anything but profit BTW
Well regarding SO "we cannot comment on the investment strategy of any one investor".... Thatd be all they could say really
Nice rise over last few hours
Should lead to plenty orders if they have to get it from Versarien surely.....................
The innovation team have pioneered this breakthrough material in to help significantly reduce CO2 emissions in construction. The production of cement - the 'glue' for concrete - is one of the leading causes of global carbon dioxide emissions, producing around 8% of global CO2 emissions.
The addition of tiny amounts of graphene..............
Nationwide Engineering estimates that an additional cost of 5% for Concretene will be offset by the reduction in material to deliver an overall saving of 10-20% over standard RC30 concrete.
There's no doubt Keytruda is a life saving / prolonging blockbuster ......... If 4D can add value to Keytruda the benefits will be amazing for so many (and I don't mean in financial terms)
MSD are building an R&D plant alongside a facility they recently acquired in Ireland. It's their first such venture so acquiring 4D would make sense.
https://www.irishtimes.com/business/health-pharma/msd-announces-240-new-jobs-with-expansion-at-dunboyne-1.4432974
Look at the numbers in that article for a site compared to 4d market cap !!!!
A buyout would need to be at x5 current SP minimum IMO
Indeed, 5% rise in less than an hour.......... someone knows something
Great start to today, I was anxious enough after yesterday afternoon but all ok now again.
The Nasdaq factor is well known, charts are oblivious to it but I fear the market isn't. I struggle to understand why we aren't much higher than current levels but I think NASDAQ won't do much for us until we've news post NASDAQ.
Yes, another great RNS, I'm amazed we aren't over 150p now to be honest.